Turning genetic data into prescribing guidance.
Pharmacyp is a clinical decision support company closing the gap between pharmacogenomic testing and clinical utility — at the moment a prescription is written, not weeks afterward in a separate report.
Two failure modes, neither of them personalized medicine.
Most healthcare systems operate in one of two ways. The first ignores pharmacogenomics entirely — prescribing without accounting for individual genetic variation, exposing patients to preventable adverse reactions, avoidable hospitalizations, and in some cases death.
The second recognizes the value of pharmacogenomic testing and invests in it, but produces reports that sit outside the clinical workflow, making it difficult for prescribers to act on them under time pressure. Neither model reflects what evidence-based, personalized medicine should look like.
A test you take once, actionable for life.
Every patient metabolizes drugs differently. Genetic variants in the CYP enzymes — the primary drug-metabolizing pathway in humans — determine whether a standard dose is therapeutic, toxic, or ineffective for a given individual. This is not a niche concern: CYP polymorphisms shape responses to medications across virtually every therapeutic area.
Critically, a pharmacogenomic test is performed once and remains actionable for the rest of a patient’s life. The clinical and economic case is well established — PGx-guided prescribing reduces adverse drug reactions, decreases hospitalizations, and has proven cost-effective across multiple health systems and therapeutic areas. The barrier is not evidence. It is implementation.
Context in the workflow, not adjacent to it.
Pharmacyp integrates CYP genotype data with real-time drug-interaction screening, and surfaces actionable recommendations directly at the point of prescribing. Rather than generating a separate report for a clinician to interpret under time pressure, the system flags genotype-specific risks and drug–drug interactions within the workflow itself — where the decision is actually made.
The physician decides. Pharmacyp adds the context that makes that decision safer, and shows the clinical guideline behind every flag on the same line.
CYP star-allele genotype → phenotype, mapped to dosing guidance for the drugs that matter.
Curated drug–drug and class-level interaction screening, severity-tiered and reproducible.
Every recommendation cites the clinical guideline that backs it. Nothing fabricated. Nothing implied.
Built by someone who reads the prescription and the paper.
Pharmacyp was founded by Filipe Burmester — a medical student and self-taught software engineer. The product is a direct response to the gap he observed between what the pharmacogenomic literature says should happen at the point of prescribing and what actually does. The mission is narrow on purpose: turn the evidence into something a prescriber can act on inside the two minutes they have with the chart open.
Personalized medicine is an implementation problem.
Pharmacyp is the implementation. Create a clinician account to see how a genotype-aware, source-transparent prescription report reads in practice.